After years of effort to develop active cancer immunotherapies, seven candidate products
achieved promising results in phase I/II studies that triggered phase III randomized studies …

Despite the progress that has been made in other forms of cancer therapy,
Provenge®(Sipuleucel-T) is the only FDA-approved vaccine for the treatment of cancer. To …

Therapeutic cancer vaccines are an emerging and potentially effective treatment modality.
Cancer vaccines are usually very well tolerated, with minimal toxicity compared with …

Advances in molecular and cellular biology as well as biotechnology led to definition of a
group of drugs referred to as medicinal products of advanced technologies. It includes gene …

Most of the recent randomised clinical trials of therapeutic cancer vaccines have failed to
demonstrate a meaningful therapeutic benefit to patients over existing treatments …

To prove clinical benefits of cancer vaccine is currently difficult, except for one phase III trial
has documented improved overall survival with the vaccine, Sipuleucel-T, although …

Immunotherapy in the treatment of cancer is increasing, particularly with the recent FDA
approval of sipuleucel-T and ipilimumab. The efficacy of anti-tumor immunotherapies has …

Background: Cancer vaccines are a unique approach to cancer therapy. They exert an
antitumor effect by engaging the host immune response, and have great potential for …

Cancer immunotherapy has seen a tremendous number of failures and only few recent
regulatory successes. This is a review dedicated to determine major regulatory and …

To the Editor: Cancer immunotherapy has a rich history spanning more than 100 years. Yet
the field has struggled to integrate its knowledge into methodological advances that enable …